Answers are grounded in this paper and cite their sources.
The generation of reactive oxygen species (ROS) during myocardial ischemia (I)/reperfusion (R) contributes to postreperfusion cardiac injury. The increase in ROS is attributed in part to the uncoupling of endothelial nitric oxide synthase (eNOS) that produces ROS instead of nitric oxide (NO) and mitochondrial derived ROS which in part is derived from opening of mitochondrial ATPsensitive K + channels (mK ATP ). Both the activity of uncoupled eNOS and the opening of mK ATP channels in mitochondria are stimulated by protein kinase C epsilon (PKC) that is activated during reperfusion. We hypothesize that a cell permeable PKC peptide inhibitor, (N-myristic acid-EAVSLKPT, Myr-PKC-) given at reperfusion will improve postreperfused cardiac function and attenuate infarct size compared to untreated isolated perfused rat hearts subjected to ischemic reperfusion injury.
No takes yet. Share an insight, caveat, or question.
McIntyre et al. (2017) studied this question.
Synapse has enriched 6 related papers. Consider them for comparative context: